New Filings At The EMA
Executive Summary
New medicines under evaluation at the European Medicines Agency. This article was updated on March 1.
You may also be interested in...
EU Accelerated Assessment Tracker 2018: Rejection Rates Remain High
The European Medicines Agency will fast-track Shionogi’s new antibiotic, cefiderocol, through regulatory review when the company files for approval but there’s no special treatment for Roche’s new tissue agnostic oncologic, entrectinib. More than half the accelerated assessment requests made in 2018 to the EMA failed to make the grade.
Slew Of New Drugs Accepted For EU Market Review, Three For Fast Track
Four orphan drugs, Roche’s tissue agnostic cancer treatment entrectinib, and a single-dose oral vaccine for cholera are among the raft of new products that the European Medicines Agency has started to review for potential approval across the EU.
EMA Probe Finds No Link Between GLP-1s And Suicidal Thoughts & Actions
After reviewing the evidence from non-clinical studies, clinical trials, post-marketing surveillance data and other studies, the European Medicines Agency said there was no need to update the product information for 11 diabetes and weight management drugs.